The groundbreaking ceremony for the Northern Operation Headquarters and Industrialization Base of Jiangsu Hengrui Pharmaceuticals Co was held in Beijing E-Town on March 12. 

This is one of the key projects in Beijing this year, covering an area of nearly 100,000 square meters. 

Kong Lei, deputy secretary of the Working Committee of Beijing E-Town, and Liu Li, deputy director of the Administrative Committee of Beijing E-Town, attended the event and initiated the project.

The groundbreaking ceremony for the Northern Operation Headquarters and Industrialization Base of Hengrui Pharma [Photo/beijingetown.com.cn]

The project commencing construction this time will be built according to international advanced standards, introducing top talents and equipment to establish the Hengrui Northern Operation Headquarters, Global Clinical Trial Management Center, Biomedical Innovation Drug R&D Center, and Industrialization Base.

As an innovative international pharmaceutical company, Hengrui Pharma focuses on research and development of new medicines in various fields such as anti-tumor, metabolic diseases, autoimmune diseases, respiratory diseases, and neurological diseases, making it one of the most innovative pharmaceutical leading enterprises in China.

At the scene of the event, workers and vehicles such as excavators, adorned with red ribbons, are all geared up and ready to go. [Photo/beijingetown.com.cn]

Previously, attracted by the industrial ecology and business environment, Hengrui Pharma settled its Northern Operation Headquarters and Industrialization Base project in E-Town. 

It has already established a wholly-owned subsidiary - Beijing Shengdi Medicine Co, responsible for the construction and operation of the project. Meanwhile, with the support of Beijing E-Town, Hengrui Pharma has three Class 1 biomedical innovative drugs currently under clinical application declaration at the Beijing base.

After the completion of this project, Hengrui Pharma will further develop and industrialize more innovative medicines in areas such as cardiovascular diseases at the Beijing base, aiming to build E-Town into another internationalized innovation and industrialization base for Hengrui.

As of now, E-Town has gathered more than 4,200 companies in the entire field of pharmaceutical and health industries, including chemical drugs, biological drugs, modern Chinese medicine, new vaccines, high-end medical equipment, and third-party service platforms. 

In 2023, the output value of biotechnology and big health industry reached 90 billion yuan ($12.51 billion), accounting for half of the city's total, preliminarily forming a development ecosystem with a scale aggregation and sound industrial chain.